South-East Asia (WHO region) vs Syria: HIV-positive TB patients on ART (antiretroviral therapy)
South-East Asia (WHO region)
94.0%
in 2024
Syria
100.0%
in 2021
South-East Asia (WHO region) rank
4th
Syria rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- South-East Asia (WHO region)
- Syria
How they compare
Syria currently reports 100.0% against 94.0% in South-East Asia (WHO region), a difference of 6.0%.
That makes Syria's figure about 1.1 times South-East Asia (WHO region)'s.
Across all 11 years both countries report, Syria has been ahead every year.
South-East Asia (WHO region) ranks 4th and Syria ranks 1st of 11 groups.
Syria has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | South-East Asia (WHO region) | Syria | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 17.0% | 100.0% | 83.0% | Syria |
| 2010s | 77.6% | 100.0% | 22.4% | Syria |
| 2020s | 89.0% | 100.0% | 11.0% | Syria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), South-East Asia (WHO region) or Syria?
- Syria, at 100.0% against 94.0% in South-East Asia (WHO region) as of 2021.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between South-East Asia (WHO region) and Syria?
- 6.0%, with Syria ahead.
- How many years of comparable data are there for South-East Asia (WHO region) and Syria?
- 11 years are reported by both, from 2007 to 2021.
- How do South-East Asia (WHO region) and Syria rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- South-East Asia (WHO region) ranks 4th and Syria ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.